CD8A and neoplasm: The authors found that intrathecal administration of B-cell depleting anti-CD20 antibodies resulted in significantly longer survival than the IgG control and this was accompanied by an increase in tumor-infiltrating granzyme B and IFNγ-expressing effector CD8+ T-cells (Lee-Chang et al., 2019).